New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
06:22 EDTESRX, CVS, HZNPHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Horizon Pharma (HZNP) said it has been verbally notified that in August, two pharmacy benefit managers, CVS Caremark (CVS) and Express Scripts (ESRX), expect to announce DUEXIS and VIMOVO will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. As a change in Caremark and ESI formulary status would not take effect until 2015, Horizon Pharma does not expect this potential action to impact the financial guidance of $270M-280M for net revenues and $80M-90M for adjusted EBITDA for fiscal 2014 as provided in first quarter earnings press release dated May 9. In response to potentially being placed on Caremarkís and ESIís exclusion lists, the company said it will immediately accelerate patient and physician focused commercial model to focus prescriptions through other channels such as our Prescriptions Made Easy program, continue working with many of the other PBMs and evaluate price increases. We estimate approximately 20%-30% of DUEXIS and VIMOVO prescriptions could be impacted by the potential actions by Caremark and ESI. In the future, if additional healthcare plans adopt the Caremark or ESI exclusion lists or otherwise exclude DUEXIS or VIMOVO from the formularies they use, which they are not required to do, there could possibly be additional DUEXIS and VIMOVO prescriptions affected.
News For HZNP;CVS;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2015
16:13 EDTESRXExpress Scripts sees Q3 adjusted EPS $1.41-$1.45, consensus $1.43
Subscribe for More Information
16:11 EDTESRXExpress Scripts reports Q2 adjusted EPS $1.44, consensus $1.40
Subscribe for More Information
15:21 EDTESRXNotable companies reporting after market close
Subscribe for More Information
July 27, 2015
16:45 EDTHZNPLone Pine Capital reports 5.4% passive stake in Horizon Pharma
Subscribe for More Information
07:09 EDTHZNPHorizon Pharma announces collaboration with Fox Chase Cancer Center
Horizon Pharma announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma and renal cell carcinoma. Preclinical cell line research has indicated that interferon gamma enhances cellular PD-L1 expression on endothelial cells and on some tumor cells. By enhancing cellular PD-L1 expression on tumor cells, interferon gamma may promote or enhance the effect of the PD-1 or PD-L1 inhibitors.
July 24, 2015
11:09 EDTHZNPWallachBeth does not see Horizon facing competing suitor for Depomed
Subscribe for More Information
July 22, 2015
05:22 EDTESRXStocks with implied volatility movement; LOCK ESRX
Subscribe for More Information
July 21, 2015
12:39 EDTESRXCiti analyzes a potential Express Scripts takeout by Walgreens Boots Alliance
Subscribe for More Information
11:28 EDTHZNPDepomed says revised Horizon proposal includes no change to amount of stock
Depomed (DEPO) confirmed that it has received a "purported revised, highly conditional, unsolicited and non-binding" proposal from Horizon Pharma (HZNP) to acquire all of the outstanding shares of Depomed in an all-stock transaction currently valued at $33.00 per share. Depomed said its board, in consultation with its independent financial and legal advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the company and its shareholders. Depomed added: "Today's purported increase does not reflect any increase in the amount of Horizon stock that the Depomed shareholders would receive, nor any increase in the pro-forma ownership for the Depomed shareholders, and is the result of the trading value of Horizon's stock having increased since it made its initial offer." Depomed previously rejected the prior proposal, made May 27, to acquire all outstanding common shares of Depomed in an all-stock transaction then valued at $29.25 per share.
07:02 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
Horizon Pharma (HZNP) announced that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60% premium to the closing price of Depomed on July 6, the day prior to when Horizon's initial proposal was made public.
07:01 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
July 20, 2015
10:33 EDTHZNPDepomed suitor Horizon Pharma advances after raising outlook
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says 'here to stick it out' regarding Depomed deal
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says Depomed proposal 'shareholder friendly'
Subscribe for More Information
09:22 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
07:16 EDTHZNPHorizon Pharma up 5.2% after reporting preliminary Q2 revenue, raises FY15 view
Subscribe for More Information
07:05 EDTHZNPHorizon Pharma raises FY15 revenue guidance to $660M-$680M from $590M-$610M
Consensus $611.6M. Raises FY15 adjusted EBITDA guidance to $265M-$280M from $235M-$250M.
07:04 EDTHZNPHorizon Pharma sees Q2 revenue $170M-$172M, consensus $138.26M
July 17, 2015
10:56 EDTCVSCVS investigates credit card breach at online photo unit, KrebsOnSecurity says
Subscribe for More Information
July 16, 2015
10:04 EDTHZNPHigh option volume stocks
High option volume stocks: TWX PMCS SHW ASML GRMN GSAT ROVI ALLY LC HZNP
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use